Tech Company Financing Transactions
Triveni Bio Funding Round
Triveni Bio, based in Waltham, received $115 million from Goldman Sachs, Atlas Venture and Cormorant Asset Management.
Transaction Overview
Company Name
Announced On
10/2/2024
Transaction Type
Venture Equity
Amount
$115,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance second-generation anti-kallikrein 5/7+IL-13 bispecific (TRIV-573) through clinical proof-of-concept.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 Beaver Street 307
Waltham, MA 02453
USA
Waltham, MA 02453
USA
Phone
Undisclosed
Website
Email Address
Overview
Triveni Bio is breaking new ground on the identification of novel disease targets -- working at the convergence of human genetics, best-in-class antibody design, and precision medicine. We are pioneering a Mendelian genetics-informed precision medicine approach to develop functional antibodies for the treatment of immunological and inflammatory (I&I) disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Vishal Patel
Chief Scientific Officer
Jennifer Dovey
Browse more venture capital transactions:
Prev: 10/2/2024: Permanent Agriculture venture capital transaction
Next: 10/2/2024: Mithradote Bio venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC transactions reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs